Patricia Carr Sells 1,117 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CAO Patricia Carr sold 1,117 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $190.91, for a total transaction of $213,246.47. Following the completion of the transaction, the chief accounting officer directly owned 9,235 shares in the company, valued at $1,763,053.85. This trade represents a 10.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Patricia Carr also recently made the following trade(s):

• On Thursday, February 26th, Patricia Carr sold 1,253 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $194.11, for a total value of $243,219.83.
• On Friday, December 5th, Patricia Carr sold 4,660 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $171.20, for a total value of $797,792.00.

Jazz Pharmaceuticals Trading Up 0.2%

Shares of JAZZ traded up $0.44 during midday trading on Monday, reaching $190.46. The company had a trading volume of 725,871 shares, compared to its average volume of 1,139,928. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $198.00. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00. The firm has a 50 day simple moving average of $169.64 and a 200-day simple moving average of $151.92. The stock has a market cap of $11.72 billion, a PE ratio of -31.90, a price-to-earnings-growth ratio of 0.38 and a beta of 0.22.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.49 by $0.15. The firm had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. Jazz Pharmaceuticals’s quarterly revenue was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.51 earnings per share. Research analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on JAZZ shares. TD Cowen reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Barclays initiated coverage on shares of Jazz Pharmaceuticals in a research report on Friday. They issued an “overweight” rating and a $224.00 target price on the stock. Morgan Stanley lifted their price target on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 29th. Finally, UBS Group restated a “neutral” rating and issued a $188.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Fourteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $214.57.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC grew its stake in Jazz Pharmaceuticals by 754.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 234 shares in the last quarter. Hilltop National Bank purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $36,000. Hantz Financial Services Inc. grew its position in shares of Jazz Pharmaceuticals by 471.4% during the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 297 shares in the last quarter. LRI Investments LLC acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth about $38,000. Finally, Danske Bank A S purchased a new stake in shares of Jazz Pharmaceuticals during the third quarter worth approximately $40,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.